logo
Sign in

VCEL Stock Price, Chart, Stats & News

Vericel Corp Ord
Save

Vericel Corp Ord (VCEL) does not currently pay a dividend.

2.43B
Market cap
113.07x
Current P/E
99.01x
Forward P/E

VCEL chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
74.42%
Operating margin
4.00%
Pretax margin
6.29%
Net margin
5.98%
Effective tax rate
4.94%
ROA
3.39%
ROE
5.17%
D/E
0.28x
Interest coverage ratio
17.53x

VCEL valuation

P/E
113.07x
P/S
5.39x
P/B
4.19x
P/CF
28.59x
P/FCF
42.47x
P/OCF
28.59x
PEG
3.89x
EV multiple
50.16x

About

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children.

Similar securities

Based on sector and market capitalization

Report issue